Authors
Nandakumar Srinivasan, Isai Pratha Karthik, Rajalakshmi Deivendran, Sujoy Sow Mondal, Jithin Ponnazhakathu Viswaswaran, Lavanya Sivakumar, Sourav Nath, Balakrishnan Solaimuthu, Jayaprakash Periyasamy, Manikandan Lakshmanan, Sundarasamy Mahalingam
Published in
Journal of molecular biology. Pages 170101. Nov 20, 2026. Epub Nov 20, 2026.
Abstract
RAS effectors play pivotal roles in regulating cytoskeletal dynamics, apoptosis, cell proliferation, survival, DNA repair, and endocytosis. However, the mechanisms by which these effectors maintain cellular homeostasis remain poorly understood. Current study identifies RAS effector RASSF8 as a novel tumor suppressor that coordinates cellular autophagy and EMT to restrain breast cancer progression. Mechanistically, RASSF8 interacts and co-localizes with autophagy markers LC3 and LAMP1, forming a trimeric complex that facilitates autophagosome-lysosome fusion into autolysosomes for cargo degradation. Furthermore, RASSF8 upregulates key autophagy-related proteins including Beclin1, ATG16L1, LAMP1, and LC3 and enhances autophagy initiation by activating the AMPK/ULK1 signaling axis via AMPK-dependent ULK1 phosphorylation. Through this induction of autophagy, RASSF8 deregulates expression of Snail, a master regulator of EMT, thereby suppressing breast cancer cell proliferation, migration, and aggressiveness. Consistent with these findings, elevated expression of RASSF8/LC3/ATG16L1 strongly correlates with improved survival of patients with breast cancer. Collectively, our findings establish a crucial mechanistic link between RASSF8 and autophagy signaling, suggesting that therapeutic approaches aimed at restoring RASSF8 function or stimulating RASSF8-mediated autophagy represent a promising strategy for anti-cancer therapeutics.
PMID:
43064340
Bibliographic data and abstract were imported from PubMed on 21 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0